COVID-19: Vaccines and Therapeutics
An AHA Member Call on Allocation and Distribution of Operation Warp Speed (OWS) Therapeutics with Nancy Foster and John Redd, MD, CMO, ASPR, including remdesivir and monoclonal antibody (MAB) therapeutics like bamlanivimab through the Emergency Use Authorization (EUA).
Moderna Inc. announced that its mRNA-1273 vaccine candidate against COVID-19 is 94.5% effective, according to early data.
As of Nov. 6, about 60% of the nation’s retail pharmacies have agreed to participate in a federal program to administer COVID-19 vaccines at no cost to patients once authorized or licensed by the Food and Drug Administration, the departments of Health and Human Services and Defense announced.
With the COVID-19 pandemic reaching the point in which vaccines against the coronavirus may soon be publicly available, the AHA is helping hospitals and health systems prepare for their arrival, while promoting public confidence in Food and Drug Administration-approved SARS-CoV-2 vaccines.
This is a set of resources to help hospitals and health systems reassure staff, patients and communities of COVID-19 vaccines’ safety and effectiveness. It includes messaging for many important audiences, whether organizational (stakeholders inside hospitals or health systems) or public-facing (…
The American Medical Association announced Current Procedural Terminology codes for reporting on medical claims two COVID-19 vaccines and their administration to patients by dose.
Pfizer Inc. announced that BNT162b2, its mRNA-based vaccine candidate, is more than 90% effective in preventing COVID-19, based on early data that has yet to be peer-reviewed.
German biotech firm CureVac N.V. announced interim data from its ongoing Phase 1 dose-escalation study evaluating its CVnCoV SARS-CoV-2 vaccine candidate for safety, reactogenicity and immunogenicity.
The Centers for Medicare & Medicaid Services announced an interim final rule establishing additional Medicare hospital payment to support Medicare beneficiaries’ access to COVID-19 vaccines and new treatments when they become available.
A COVID-19 vaccine is likely coming soon. Whether it’s next month, at the end of the year or in early 2021, many scientific experts believe we will have one or more safe and effective vaccines to combat the deadly virus.